CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

The Use of Naltrexone for Dissociation during Eye Movement Desensitization and Reprocessing Treatment: Clinical Effectiveness and Guidelines

Last updated: March 29, 2017
Project Number: RB1079-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness regarding the use of naltrexone to treat dissociation during eye movement desensitization and reprocessing treatment in patients suffering from posttraumatic stress disorder, anxiety, and/or mood disorders?
  2. What are the evidence-based guidelines regarding the use of naltrexone to treat dissociation during eye movement desensitization and reprocessing treatment in patients suffering from posttraumatic stress disorder, anxiety, and/or mood disorders?

Key Message

No relevant literature was identified regarding the clinical effectiveness of Naltrexone during eye movement desensitization and reprocessing treatment for adults and veterans with posttraumatic stress disorder, anxiety disorder, and/or mood disorders.